Royal Bank Of Canada Next Cure, Inc. Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.17 - $2.49 $451 - $961	386 Added 2270.59%	403 $0
Q1 2024 Nov 05, 2024	SELL	$1.13 - $2.23 $436 - $860	-386 Reduced 95.78%	17 $0
Q1 2024 May 15, 2024	SELL	$1.13 - $2.23 $280 - $553	-248 Reduced 93.58%	17 $0
Q4 2023 Feb 14, 2024	BUY	$1.03 - $1.45 $272 - $384	265 New	265 $0
Q2 2023 Aug 14, 2023	BUY	$1.47 - $1.86 $51 - $65	35 Added 318.18%	46 $0
Q1 2023 May 15, 2023	BUY	$1.46 - $1.83 $16 - $20	11 New	11 $0
Q3 2022 Nov 14, 2022	SELL	$2.72 - $5.19 $84 - $160	-31 Reduced 15.5%	169 $0
Q3 2021 Nov 15, 2021	SELL	$6.74 - $8.02 $3,006 - $3,576	-446 Reduced 69.04%	200 $1,000
Q2 2021 Aug 16, 2021	BUY	$7.6 - $10.28 $4,909 - $6,640	646 New	646 $6,000

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $36.4M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.